This session taking place on International Clinical Trials Day will focus specifically on innovative trial design and its application in cancer research.
The session will describe cancer research’s rich history in developing innovative trials before looking specifically at five trials with novel designs. By the end of the session, participants will have a better understanding of how innovative designs can be applied successfully to cancer-related trials.
- Professor Emma Hall – The Institute of Cancer Research, UK
- Ms Amy Kirkwood – Cancer Research UK & UCL Cancer Trials Centre, UK
- Dr Laura Clifton Hadley – Cancer Research UK & UCL Cancer Trials Centre, UK
The study builds on the experience of previously successful treatments for children and young adults with acute lymphoblastic leukaemia (ALL), with a new platform protocol, which is both a comprehensive system for stratification and treatment of ALL, as well as the basis for several randomised trials included in the study design.
- Professor Terry M Jones – University of Liverpool, UK
- Professor Mererid Evans – Velindre Cancer Centre, UK
PATHOS is a Phase III trial looking at less intensive treatment after surgery for human papillomavirus (HPV)-positive oropharyngeal cancer to assess whether swallowing function can be improved. The aim of the trial is to personalise treatment based on disease biology (HPV status and pathology findings) and to optimise patient outcomes.
- Ms Elaine McCartney – Cancer Research UK Glasgow Clinical Trials Unit, UK
The CAVA trial compared different types of central lines used to give long term chemotherapy. It was a pragmatic, open-label, multicentre, mixed methods, randomised controlled trial of three routinely used central lines: tunnelled central lines, PICC lines and portacath.
- Dr Elena Frangou – University College London, UK
RAMPART is an international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trials of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
- Mr Geoff Saunders – University of Southampton, UK
AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19.
The trial demonstrates both how to design and deliver an adaptive dose-finding trial to support uptake of modern designs for dose-finding studies.
2 category 1 (external) CPD credits for this session have been approved by the Federation of the Royal Colleges of Physicians. Delegates requiring a CPD certificate can add this during the registration process for a charge of £15. CPD Certificates will be sent automatically up to 10 days after the event date.
Who should attend?
Anyone interested or working in cancer research, particularly those who are interested in innovative trial design. This includes patients and carers formally involved in research, scientists, medical/clinical oncologists, surgeons, early career researchers, nurses, allied health professionals, PhD and undergraduate students, research teams and research managers/funders.